Background Therapeutic drug monitoring (TDM) of anti-TNF is increasingly used to manage
inflammatory bowel diseases (IBD) and rheumatoid arthritis (RA). The cost-effectiveness of …

Infliximab and adalimumab are monoclonal antibodies against tumor necrosis factor (anti-
TNF) used to manage inflammatory bowel disease (IBD). Therapeutic Drug Monitoring …

Summary Background and Aims This systematic review and meta‐analysis aimed to
determine whether the use of therapeutic drug monitoring (TDM) in inflammatory bowel …

Background There is a growing body of primary evidence on the cost-effectiveness of
applying therapeutic drug monitoring (TDM) for inflammatory bowel disease (IBD) …

Abstract Background and Aims Empirical dose intensification and therapeutic drug
monitoring [TDM] of infliximab [IFX] trough levels [ITLs] and antibody to infliximab [ATI] …

Abstract Background and Aims We undertook a systematic review and meta-analysis
examining the effectiveness of therapeutic drug monitoring [TDM] to improve clinical …

Background Therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD)
patients receiving anti‐tumour necrosis factor (TNF) agents can help optimise outcomes …

Background & Aims Proactive therapeutic drug monitoring (TDM) has been proposed to
improve outcomes in patients with inflammatory bowel disease (IBD) treated with tumor …

After the introduction of anti-tumor necrosis factor (anti-TNF) agents, the clinical outcome of
patients with Inflammatory Bowel Disease (IBD) has improved significantly. However, use of …

Background Therapeutic drug monitoring (TDM) is increasingly performed for Infliximab
(IFX) in patients with Crohn's disease (CD). Reactive TDM is a cost-effective strategy to …